MARKET

ORXOY

ORXOY

Orexo Ab
OTCQX
2.960
NaN%
Closed 09:30 03/05 EST
OPEN
--
PREV CLOSE
2.800
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.050
52 WEEK LOW
1.570
MARKET CAP
--
P/E (TTM)
1.479
1D
5D
1M
3M
1Y
5Y
1D
Orexo AB Board Converts 416,417 Class C Shares to Ordinary Shares and Transfers 416,417 Ordinary Shares Under LTIP 2023–2025
Reuters · 02/19 16:33
Orexo AB posts Q4 2025 net earnings of SEK 724.8 million after Zubsolv divestment
Reuters · 02/05 06:03
Orexo AB erzielt im vierten Quartal 2025 einen Nettoertrag aus fortgeführten Aktivitäten von -115,6 Mio. SEK, was einer Verbesserung um 35 Prozent entspricht
Reuters · 02/05 06:03
Orexo Sells Zubsolv US Business to Dexcel Pharma USA
Reuters · 12/22/2025 20:02
Orexo AB Secures BARDA Partnership for Development of OX390 Overdose Rescue Therapy
Reuters · 12/05/2025 08:00
Weekly Report: what happened at ORXOY last week (0908-0912)?
Weekly Report · 09/15/2025 09:35
Weekly Report: what happened at ORXOY last week (0901-0905)?
Weekly Report · 09/08/2025 09:37
Weekly Report: what happened at ORXOY last week (0825-0829)?
Weekly Report · 09/01/2025 09:35
More
About ORXOY
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Webull offers Orexo AB - ADR stock information, including OTCQX: ORXOY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORXOY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORXOY stock methods without spending real money on the virtual paper trading platform.